Related Experiment Video
Updated: Apr 4, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Rating Apathy in Huntington’s Disease: Patients and Companions Agree
1John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK. slm64@cam.ac.uk
Insights
Self-rated apathy scores in Huntington's disease (HD) align with companion ratings and remain stable over 18 months. This validates patient self-assessment for apathy in HD research and clinical practice.
Area of Science:
- Neurodegenerative diseases
- Neurology
- Psychiatry
Background:
- Apathy is a prevalent symptom in Huntington's disease (HD), manifesting even in early stages.
- Patients with HD often lack self-awareness regarding their apathy, necessitating reliance on clinician or companion assessments.
- The longitudinal progression of apathy in HD has not been clearly defined.
Purpose of the Study:
- To assess the concordance between self-reported apathy and companion-reported apathy in Huntington's disease patients.
- To investigate the clinical correlations of apathy with motor, cognitive, and functional status.
- To examine the stability of apathy over an 18-month period in HD patients.
Main Methods:
- Apathy was evaluated using the Apathy Evaluation Scale in a cross-sectional cohort of 106 HD patients (early to late stage).
- A subgroup of 62 patients was followed longitudinally over approximately 18.7 months.
- Comparisons were made between self- and companion-rated apathy scores, alongside analyses of clinical correlates.
Main Results:
- A high correlation was observed between self-rated and companion-rated apathy scores in the cross-sectional analysis.
- Both self- and companion-rated apathy showed associations with motor and functional impairments, with a complex relationship to cognition.
- Longitudinal data indicated that apathy levels remained stable over the 18-month follow-up period.
Conclusions:
- Apathy in Huntington's disease can be reliably assessed by both patients and their companions.
- Apathy scores demonstrate significant stability over an 18-month timeframe in HD patients.
- These findings support the use of self-rated apathy in research and clinical settings and inform the design of therapeutic intervention studies.
Background:
Apathy is a common feature of Huntington’s disease (HD), even from early disease. However, patients are believed to lack insight into their own apathy and therefore clinicians and/or companions are relied upon to estimate the extent of a patient’s apathy. In addition, the evolution of apathy over time in HD has not been unequivocally established. OBJECTIVEs: The purpose of this study was to determine whether HD patient’s self-rated apathy scores were consistent with the scores given by companions who were also asked to rate the patients apathy. Furthermore, the clinical correlates of apathy and its stability over time were examined for both self-rated and companion-rated scores. METHODs: Apathy was measured in a large cross-sectional population of HD patients ranging from early to late stage disease (n = 106) using the Apathy Evaluation Scale; a subgroup of whom were followed longitudinally (n = 62) on average 18.7 (1.2 SD) months later. Comparisons were made between self-rated and companion-rated apathy and the relationship between apathy and motor, cognitive and functional performance was explored.
Results:
Analysis of the cross-sectional data revealed that self-rated and companion-rated apathy were highly correlated, establishing the validity of using self-rated instead of, or in combination with, companion-rated assessments of apathy in future studies. Both self-rated and companion-rated scores had a relationship with motor and functional impairment, but had a complex relationship with cognition. The results of the longitudinal comparison revealed that apathy did not change over time in this cohort.CONCLUSIONs: Apathy can be equally well assessed by either patients or companions and does not change significantly over an18 month period. These findings have implications in the design of studies looking at treating this important aspect of HD.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

